Clinical Trials Logo

Pulmonary Alveolar Proteinosis clinical trials

View clinical trials related to Pulmonary Alveolar Proteinosis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06431776 Not yet recruiting - Clinical trials for Autoimmune Pulmonary Alveolar Proteinosis

Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).

Start date: August 2024
Phase: Phase 3
Study type: Interventional

The goal of this open-label study is to study molgramostim as a treatment for autoimmune pulmonary alveolar proteinosis (aPAP) in pediatric patients between age 6 and 18. The main questions it aims to answer are: The effect of molgramostim on breathing tests and activity in pediatric patients with aPAP and the safety of molgramostim in pediatric patients with aPAP. This is an open-label study: all participants will receive treatment with molgramostim. Patients will: - Take molgramostim once daily via nebulizer every day for 12 months. - Visit the clinic approximately every 12 weeks for checkups and tests. - Keep a diary of any oxygen use.

NCT ID: NCT06111846 Not yet recruiting - Clinical trials for Autoimmune Pulmonary Alveolar Proteinosis

Study of Human Bone Marrow Mesenchymal Stem Cells in aPAP

Start date: November 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this open-label phase IIa clinical trial study is to evaluate the safety and preliminary efficacy of hBMMSC intravenous treatment in patients with aPAP.